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Abstract
Low-density lipoprotein (LDL) receptors are overexpressed in most neoplastic cell lines and provide a mechanism for the 
internalization and concentration of drug-laden nanoemulsions that bind to these receptors. The aim of the present study was 
to determine whether the administration of standard chemotherapeutic schemes can alter the expression of LDL and LDL 
receptor-related protein 1 (LRP-1) receptors in breast carcinoma. Fragments of tumoral and normal breast tissue from 16 con-
secutive volunteer women with breast cancer in stage II or III were obtained from biopsies before the beginning of neoadjuvant 
chemotherapy and after chemotherapy, from fragments excised during mastectomy. Tissues were analyzed by immunohis-
tochemistry for both receptors. Because complete response to treatment was achieved in 4 patients, only the tumors from 12 
were analyzed. Before chemotherapy, there was overexpression of LDL receptor in the tumoral tissue compared to normal 
breast tissue in 8 of these patients. LRP-1 receptor overexpression was observed in tumors of 4 patients. After chemotherapy, 
expression of both receptors decreased in the tumors of 6 patients, increased in 4 and was unchanged in 2. Nonetheless, even 
when chemotherapy reduced receptors expression, the expression was still above normal. The fact that chemotherapy does 
not impair LDL receptors expression supports the use of drug carrier systems that target neoplastic cells by the LDL receptor 
endocytic pathway in patients on conventional chemotherapy.
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Low-density lipoprotein (LDL) is removed from the cir-
culation by specialized membrane receptors that internalize 
the lipoprotein particles into cells. LDL receptors recognize 
apolipoprotein (Apo) B, which is the only Apo present in the 
LDL structure. LDL receptors are grouped in coated pits, 
depressions on the cell membrane that are reinforced by 
a clathrin cover (1). After binding of LDL receptors, clathrin 
vesicles are formed, containing the LDL particles and the 
receptors. The vesicles fuse with lysosomes and the pH in 
the interior of receptosomes falls. The vesicles dehydrate 
and disrupt and the lipid and degraded protein content is 
dispersed in the cytosol. LDL receptors recirculate back 
to coated pits in the plasma membrane (1). LDL receptors 
recognize not only Apo B but also Apo E, which is not present 
in LDL but is present in other lipoproteins such as very-low-
density lipoprotein (VLDL) or chylomicron remnants. 
LDL receptors are up-regulated in many neoplastic 
cell lines (2-4) and this phenomenon may be of prognostic 
significance (5). Most importantly, the LDL receptor endo-
cytic pathway can be used as a gate to deliver anticancer 
drugs to tumor tissues (6,7). This can be performed by 
including drugs in lipoproteins that, after injection into the 
circulation, concentrate in the cells with LDL receptor up-
regulation. In previous studies, we showed that non-protein 
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nanoemulsions that are artificially prepared and resemble 
the lipid structure of LDL can also be directed at tumors 
by the LDL receptor pathway (8). After injection into the 
blood stream, these nanoemulsions acquire Apo E from 
the native lipoproteins and bind to the LDL receptors 
through Apo E (8). 
Other studies have shown that another receptor that can 
take up lipoproteins, the LDL receptor-related protein (LRP) 
receptor can be also overexpressed in neoplastic cells (9). 
LRP receptor is a member of the LDL receptor family but 
recognizes a broader spectrum of ligands and has a wide 
spectrum of biological functions (10,11). Initially, LRP was 
thought to primarily serve as a lipoprotein receptor due to 
its resemblance to LDL receptors. In addition, LRP binds the 
blood proteins α2-macroglobulin and tissue plasminogen 
activator and its inhibitors. The LRP receptor recognizes 
Apo E of lipoproteins and binds remnants produced by the 
digestion of the triacylglycerol of chylomicrons and VLDL by 
lipoprotein lipase (12,13). The LRP receptor is abundant in 
the cell membranes of the liver, brain and placenta (14). 
Lipoprotein receptors up-regulation in neoplastic cells 
may be related to the increased need by the cell to in-
ternalize lipids such as cholesterol and phospholipids to 
build new membranes required by the accelerated mitosis 
rates (15). We have shown that, after injection into breast 
cancer patients who were scheduled to be submitted to 
mastectomy in the ensuing 24 h, nanoemulsions that pick 
up Apo E concentrated in the excised tumors several-fold 
more than in normal mammary tissue (16-18).
For a large number of patients with breast cancer, che-
motherapy is the first choice of treatment. However, the toxic-
ity of the chemotherapeutic agents and the low therapeutic 
index are strong limitations of successful treatment (19). 
Drug targeting may offer an interesting strategy to improve 
the efficiency of chemotherapy (20,21). It has been reported 
that association with a nanoemulsion dramatically reduces 
the toxicity of several chemotherapeutic agents, as shown 
in clinical trials enrolling patients with breast cancers and 
other solid or hematologic neoplasias (22,23). As overex-
pression of lipoprotein receptors is a remarkably differential 
phenomenon in neoplastic cells, characterization of these 
receptors in tumors should be extensively documented to 
favor the use of these new strategies. 
The objective of the present study was to investigate 
whether chemotherapy alters the expression of LDL and LRP 
receptors. This is a practical question regarding whether 
the tumors of patients who were already being treated 
with chemotherapeutic agents could still show receptor 
overexpression. If so, the introduction of drugs carried in 
LDL receptor binding nanoemulsions may be feasible. To 
address this issue, fragments of breast tumors and normal 
tissues excised in biopsies and during mastectomy were 
studied before and after neoadjuvant chemotherapy and 
the extent of the expression of LDL and LRP-1 receptors 
was determined by immunohistochemistry. 
Material and Methods
Subjects
Sixteen consecutive volunteer women with breast 
cancer in stage II or III who were not candidates for con-
servative surgery and with an indication of neoadjuvant 
chemotherapy participated in the study. The patients were 
selected in the Oncology Section of the Women’s Health 
Hospital (São Paulo, Brazil). The diagnosis was based on 
a previously obtained biopsy. The patients had adequate 
bone marrow function, with absolute granulocyte count 
≥1.5 x 109/L, platelet count ≥100 x 109/L, and hemoglobin 
≥10 g%. Hepatic and renal functions were also normal. 
Patients had no previous breast cancer treatment and 
had performance status ≤2, the scale commonly used 
for appraisal of an individual’s ability to manage activities 
of daily living, created by the USA Eastern Cooperative 
Oncology Group (ECOG)/World Health Organization 
(WHO) (24). 
Table 1 shows individual data such as patient age, 
histological diagnosis, grade of nuclear differentiation, clini-
cal and pathological staging, and response to neoadjuvant 
chemotherapy. All breast cancer cases were staged clinically 
and pathologically at diagnosis from 0 to 4 depending on the 
combination of TNM category (T = tumor size, N = amount of 
regional lymph node involvement, M = metastases). Grade 
of nuclear differentiation refers to the size and shape of the 
nucleus in tumor cells and the percentage of tumor cells that 
are dividing, described by four degrees of severity. These 
stagings were defined by the NCI-NIH (National Cancer 
Institute-National Institute of Health), USA, and revised by 
the American Joint Committee on Cancer Staging System 
for Breast Cancer (AJCC) (25).
Exclusion criteria were inflammatory carcinoma, meta-
static disease, multifocal disease, bilateral tumor, cardiac 
arrhythmia grade two or more, active infection, presence of 
severe psychiatric disease, or second malignancy (except 
for in situ carcinoma of the cervix or adequately treated 
basal cell carcinoma of the skin), and pregnant or nursing 
patients.
The immunohistochemical features and diagnosis of 
pathological staging were performed at the Department of 
Pathology of the Women’s Health Hospital.
The study was approved by the Ethics Committee of 
the Women’s Health Hospital (Protocol No. 0296/09) and 
all participants gave written informed consent.
Determination of serum lipids 
Blood samples for the determination of laboratory 
parameters were collected after a 12-h fast on the same 
day of the biopsy. Commercial enzymatic colorimetric 
methods were used for the determination of total cho-
lesterol, triacylglycerides and HDL-C (Labtest, Brazil). 
LDL-C was calculated according to the Friedewald 
formula (26). 
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Immunohistochemical analysis
Five-micron thick sections of formalin-fixed paraffin-
embedded tissue were routinely processed. For immuno-
histochemical analysis, the anti-LDLR rabbit antimouse 
polyclonal antibody against synthetic peptide from murine 
LDL receptor amino acids 499-511 (SVADTKGVKRRTL; 
LifeSpan Biosciences Inc., USA) and the anti-LRP anti-
mouse monoclonal antibody against the 5A6 clone (Cal-
biochem, Germany) were used in this study. Specificity of 
the antibody was tested in mouse liver fragments, which is 
a standard procedure, since the liver expresses the highest 
amount of LRP (Figure 1).
For immunostaining for LRP-1, antigen retrieval was 
performed by heating with 10 mM citrate buffer, pH 6.0, 
for 30 min and cooling for 5 min at room temperature. For 
immunostaining for LDLR, antigen retrieval was not nec-
essary. Endogenous peroxidase activity was blocked by 
incubation in 3% hydrogen peroxide. Briefly, each tissue 
section was incubated in fetal calf serum for 1 h at 42°C. 
The slides were then incubated overnight at 4°C with a 
1:50 dilution of anti-LDLR antibody or with a 1:400 dilution 
of anti-LRP antibody. Next, the sections were incubated for 
30 min at room temperature with a SuperPicture Polymer 
Detection System (Invitrogen Co., USA). The sections were 
incubated with a 3,3’-diamino-benzidine (DAB) chromogen 
system (Dako America Inc., USA) for 1.5 min at room 
temperature and then counterstained with hematoxylin. 
Between incubations, the slides were rinsed three times for 
5 min with PBS. In the negative control experiment, both 
primary antibodies were replaced with 1% bovine serum 
albumin (Figure 1).
For quantitative image analysis of immunostaining for 
LDL and LRP-1 receptors, the color detection threshold 
was chosen for the DAB chromogen in tissue sections. The 
settings for chromogen staining were optimized so that all 
cells that were identified as labeled above background by 
visual inspection were also scored by the image analysis 
software. Multiple fields (2-6 depending on section size) 
from each section were captured at 200X magnification 
by means of the Image Analysis System Quantimet 500+ 
(Leica Cambridge Ltda., UK) and the area was calculated 
as percentage of the area immunostained in each field. The 
mean for each patient was calculated based on all fields 
measured in each section.
Results
Table 1 shows the clinical staging, as established before 
the beginning of chemotherapy, and the pathological stag-
ing established by the examination of the tissue fragments 
excised during surgery. Among 16 subjects, only 4 presented 
complete response to chemotherapy.
The quantitative analysis of the estrogen and progester-
one receptors and human epidermal growth factor receptor-
type 2 (HER-2) status is shown in Table 2. Eight patients 
presented positivity for hormonal receptors, 3 presented 
HER-2 hyperexpression, and 5 were characterized as triple 
negative (estrogen receptor (ER), progesterone receptor 
(PgR), and HER-2 negative).
Table 3 shows the chemotherapy regimen used in each 
subject with the number of cycles performed. The patients 
received 4 to 11 chemotherapy cycles. 
Regarding the plasma lipid profile before the beginning 
of chemotherapy, total cholesterol was 231 ± 68 (mean ± 
standard deviation), LDL-C was in 141 ± 65, HDL-C was 
63 ± 20, and triglycerides were 136 ± 65 mg/dL.
 
Immunohistochemistry of LDL receptor 
Table 4 shows the expression of LDL receptor in normal 
tissue and in tumor tissue before and after chemotherapy. 
Because of the absence of tumor in the surgical frag-
ments, patients who presented a complete response to 
chemotherapy were excluded from this analysis. Eight of 11 
patients evaluated presented higher LDL receptor expres-
sion in tumor tissue than in normal tissue. For 3 patients, 
however, LDL receptor expression was lower in the tumor 
than in the normal tissue. 
Chemotherapy reduced the expression of LDL recep-
tor in the tumor tissue of 6 patients. However, in 4 patients 
the expression of the LDL receptor increased and in 2 it 
was unchanged. 
Among the 8 patients who presented tumors with high 
LDL receptor expression before chemotherapy, 2 showed a 
further increase in LDL receptor expression, in 1 the recep-
tor expression was unchanged, whereas in 5 patients the 
receptor expression was reduced after chemotherapy. In 
3 of the 5 patients the receptor expression of tumor tissue 
was still higher than that of normal tissue.
Among the 3 patients who showed LDL receptor expression 
in the tumor before chemotherapy, chemotherapy elicited dif-
ferent responses: in 1 the LDL receptor expression increased, 
in 1 it decreased, and in the other it was unchanged.
Immunohistochemistry of LRP-1 receptor
Table 5 presents LRP-1 receptor expression in normal 
tissue compared to tumor tissue before and after chemo-
therapy. Among 12 patients evaluated, receptor expres-
sion in tumor tissue was increased in 4 and decreased in 
3 compared to the corresponding normal tissue. In 5 the 
expression of LRP-1 receptor was the same in tumors and 
in normal tissues. 
After chemotherapy, the expression of the LRP-1 recep-
tor was reduced in the tumors of 6 patients, increased in 
4, and unchanged in 2. 
Among the 4 patients who showed tumors with high 
LRP-1 receptor expression before chemotherapy, the 
receptor expression was reduced after chemotherapy in 
2, whereas in 2 there was a further increase in the LDL 
receptor expression. 
Among the 3 patients who showed tumors with low 
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Figure 1. Photomicrograph of human breast tumor tissue and mouse liver tissue, indicating the negative and positive controls of the 
immunohistochemistry protocol for low-density lipoprotein (LDL) receptor (A, C and E) and LDL receptor-related protein 1 receptor (B, 
D and F). A and B, Negative control, performed in human breast tissue, in which the primary antibody was replaced with bovine serum 
albumin. C and D, Positive control, performed in mouse liver, which shows the highest protein expression of lipoprotein receptors. E 
and F, Immunohistochemistry performed in human breast tumor tissue. Brown staining (arrows) indicates the expression of lipoprotein 
receptors immunostained by DAB chromogen. 
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Table 1. Age, histological diagnosis, grade of nuclear differentiation, clinical and pathological stag-
ing (CS and PS), and response to neoadjuvant chemotherapy of the patients in the present study.
Patients Age 
(years)
Histological
diagnosis
G Clinical staging Pathological 
staging
Response
   T N CS T N PS
 1 58 IDC 2 4b 1 IIIB 4b 1a IIIB ICR
 2 53 ILC 1 3 1 IIIA 4 1 IIIB ICR
 3 53 IDC 2 3 0 IIB 4b 1a IIIB ICR
 4 34 IDC 2 3 2 IIIA 4 3a IIIC ICR
 5 64 IDC 2 2 2 IIIA 2 2a IIIA ICR
 6 60 IDC 2 4b 1 IIIB 4b 3 IIIC ICR
 7 40 IDC 2 4b 1 IIIB 4b 2 IIIB ICR
 8 48 IDC 2 3 2 IIIA 4 2 IIIB ICR
 9 49 IDC 1 3 2 IIIA 2 3 IIIC ICR
10 63 IDC 3 4b 2 IIIB 4 0 IIIB ICR
11 53 IDC 3 3 1 IIIA 1c 1a IIA ICR
12 41 IDC 2 3 1 IIIA 2 1 IIB ICR
13 37 IDC 2 3 2 IIIB 0 0 0 CR
14 51 IDC 2 3 3 IIIC 0 0 0 CR
15 46 IDC 2 3 2 IIIB 0 0 0 CR
16 48 IDC 2 2 1 IIB 0 0 0 CR
IDC = invasive ductal carcinoma; ILC = invasive lobular carcinoma; G = grade of nuclear differen-
tiation; T and N = tumor and node of the TNM staging system; ICR = incomplete response; CR = 
complete response. 
Table 2. Quantitative analysis of the estrogen and progesterone 
receptors and HER-2 status before chemotherapy.
Patients Estrogen 
receptor
Progesterone 
receptor
Cerb-B2
 1 >75% positive 25% positive Negative
 2 75% positive Negative Negative
 3 Negative Negative 3+/3+
 4 50-75% positive Negative Negative
 5 25-50% positive Negative 2+/3+
 6 25% positive Negative Negative
 7 10-25% positive Negative Negative
 8 50% positive <25% positive Negative
 9 Negative Negative 3+/3+
10 Negative Negative Negative
11 Negative Negative Negative
12 Negative Negative Negative
13 Negative Negative Negative
14 Negative Negative 3+/3+
15 >75% positive Negative 2+/3+
16 Negative Negative Negative
Cerb-B2 = human epidermal growth factor receptor 2; 2+/3+ = 
doubtful result; 3+/3+ = positive result for Cerb-B2 status. 
Table 3. Chemotherapy regimen and cycles performed.
Patients Chemotherapy 
regimen
Number of 
chemotherapy cycles
 1 AC 4
 2 AC 4
 3 AC + DCT 4 + 4 = 8
 4 AC 4
 5 GCT/DDP 6
 6 ADM/DDP + GCT/DDP   5 + 6 = 11
 7 ADM/DDP 6
 8 PCT/ADM 8
 9 PCT/ADM 6
10 GCT/DDP 6
11 AC 4
12 GCT/DDP 6
13 ADM/DDP 6
14 PCT/GCT 8
15 PCT/GCT 6
16 ADM/DDP 6
AC = doxorubicin + cyclophosphamide; DCT = docetaxel; GCT/
DDP = gemcitabine + cisplatin; ADM/DDP = doxorubicin + cispla-
tin; PCT/ADM = paclitaxel + doxorubicin; PCT/GCT = paclitaxel 
+ gemcitabine. 
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LRP-1 receptor expression before chemotherapy, the re-
ceptor expression was reduced after chemotherapy in 2, 
whereas it was further increased in one. 
Among the 5 patients who showed unchanged LRP-1 
receptor expression in the tumor before chemotherapy, 
treatment elicited different responses: in 1 the LRP-1 re-
ceptor expression increased, in 2 it decreased, and in 3 it 
was unchanged.
No correlations were found between the expression 
of both LDL and LRP receptors and PgR or ER status 
(Pearson’s correlation). 
Discussion
In this study, 8 of 11 patients showed high LDL receptor 
expression in tumor tissue before chemotherapy compared 
to the matched normal breast tissue. In our previous stud-
ies, without exception, in all 35 patients injected with the 
radioactive nanoemulsion the concentration of the tracer 
was greater in the breast tumor than in the normal tissue. 
This observation was made by either nuclear medicine 
imaging using 99Tc-labeled nanoemulsions or radioac-
tive measurement of the excised tumors after injection of 
nanoemulsions labeled with tritium before mastectomy 
(16-18,27). The fact that 3 of the 11 patients in this study 
did not show LDL receptor overexpression does not imply 
that increased uptake of lipoproteins would not occur in 
these patients. Although increased uptake of the lipoprotein 
occurs chiefly by increasing the number of lipoprotein re-
ceptors on the cell surface, other mechanisms can also be 
at work to increase uptake without an increase in receptor 
number. Acceleration of receptor recycling can be one of 
the mechanisms whereby increase in uptake could occur, 
since speeding up receptor disposal leads to enhancement 
of receptor function (23). 
On the other hand, in those tumors in which LDL receptor 
expression was higher in tumor tissue than in the corre-
sponding normal breast tissue, there was a wide variation 
in the expression data. This variation ranged from 1.4-fold 
(patient number 8) to 13-fold (patient number 3) that of 
normal tissue. A wide variation was also observed in our 
previous studies (16,17,27,28) regarding the nanoemulsion 
tissue uptake, which was greater in the tumor than in the 
normal tissue by 1.4- to 8.8-fold. Incidentally, the pattern of 
wide variation in the increase of LDL receptor expression 
has been reported in several studies since the seminal 
study by Ho et al. (2): in acute myelocytic leukemia cells, 
LDL receptor overexpression varied from 3- to 100-fold. It 
is noteworthy that in normal tissues the LDL receptors also 
showed a wide variation of expression among patients. 
This certainly reflects changes in intracellular cholesterol 
saturation and cellular demands of lipids. 
The effects of chemotherapy on the tumoral expres-
sion of LDL receptors were very heterogeneous, so that 
the interpretation of these data is difficult. Assuming that 
overexpression of receptors is caused by the accelerated 
lipid-dependent membrane synthesis, by inhibiting mitosis 
it should be expected that the receptor expression would 
decrease. Indeed, the expected effect was observed in 6 
of the patients, but in 4 patients the post-chemotherapy 
expression values were higher than the pre-chemotherapy 
ones and in 2 the expression was unchanged. This sug-
gests that the relationship between receptor expression 
and mitosis is not so straightforward or, eventually, these 
findings could also be related to drug resistance.
Table 4. LDL receptor expression in normal and tumor tissue 
pre- and post-chemotherapy determined by immunohistochem-
istry (%).
Patients Normal 
tissue
Tumor 
pre-chemotherapy
Tumor 
post-chemotherapy
 1 14.9 9.0 8.5
 2 0.5 6.0 10.3 
 3 13.5 1.9 2.4
 4 18.2 6.4 2.0 
 5 10.0 22.3 2.1 
 6 - 15.5 50.7 
 7 2.5 13.7 15.9 
 8 16.6 23.0 4.0 
 9 4.1 7.0 11.4
10 7.0 15.8 12.0 
11 2.4 18.6 5.8
12 3.6 33.7 14.3
Data are reported as percentage of cells positive to the LDLR 
antibody.
Table 5. LRP-1 receptor expression in normal and tumor tissue 
pre- and post-chemotherapy determined by immunohistochem-
istry (%).
Patients Normal 
tissue
Tumor 
pre-chemotherapy
Tumor 
post-chemotherapy
 1 3.7 4.2 0.3
 2 8.1 5.6 1.0
 3 4.7 6.2 11.3
 4 20.0 3.2 1.6
 5 2.5 4.0 1.4
 6 4.4 4.7 12.5
 7 2.4 0.3 0.5
 8 14.0 13.4 3.5
 9 5.5 7.2 4.3
10 1.4 3.3 5.4
11 4.7 5.1 5.0
12 11.0 8.5 9.1
Data are reported as percentage of cells positive to the LRP-1 
antibody.
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Regarding the LRP receptor, by comparing pre-
chemotherapy values of tumors with those of matched 
normal breast tissues, the expected pattern of increased 
expression in tumors was unclear: whereas higher tumor 
values were found in 4 patients, in 3 they were lower, and 
in 5 they were equal. In contrast to the consistent reports 
of LDL receptor overexpression in most cancers, with few 
exceptions such as lymphocytic acute leukemia, the is-
sue of whether or not there is simultaneous LRP receptor 
overexpression has been much less explored, with rather 
controversial results (9,29). The response to chemotherapy 
of LRP receptor expression was somewhat similar to that 
found in LDL receptor, with the expected decrease in ex-
pression occurring in the tumors of 6 patients, an increase 
in 4 and unchanged values in 2 patients. 
Because receptor expression is not the sole determinant 
of receptor-mediated endocytosis, studies on the uptake of 
lipoproteins or artificial nanoemulsions should be performed 
in patients to confirm the influence of chemotherapy on 
tissue uptake. 
Most of the breast tumors studied here were the inva-
sive ductal carcinoma type, which is the most common, 
accounting for approximately 85% of the total breast cancer 
incidence. Histology showed lobular invasion in only one 
case. The data obtained here about the expression of li-
poprotein receptors in this neoplasia are important in view 
of the challenging possibilities of using the LDL receptor 
endocytic pathway to concentrate anticancer drugs at their 
site of action. Our group has already shown that the use 
as drug vehicles of lipid nanoemulsions that bind to these 
receptors may provide a strong reduction of side effects. 
This was demonstrated at the clinical trial level with dif-
ferent chemotherapeutic agents such as carmustine (22), 
etoposide (28,30) and paclitaxel (17,31) and in patients with 
different solid and hematologic cancers. The animal studies 
showed that the pharmacologic action of nanoemulsion-
associated drugs was not reduced. The possibility tested 
here was whether conventional chemotherapy may diminish 
the receptor expression so that a subsequent introduction of 
nanoemulsion-based chemotherapy would be less efficient. 
Our results show that, fortunately, a reduction of receptor 
expression is not the post-chemotherapy pattern.
The fact that the PgR or ER status did not correlate with 
the expression of LDL or LRP receptors is irrelevant because 
the features that are critical for hormone therapy are not 
related to the indication or outcome of chemotherapy. 
The liver is the major site of lipoprotein and nanoemul-
sion uptake in the body and consequently of the drugs car-
ried in nanoemulsions. Nonetheless, in animals implanted 
with B16 melanoma or Walker tumor, we showed that dif-
ferent drugs carried in nanoemulsions that bind to LDL re-
ceptors, such as carmustine (32), etoposide (33), paclitaxel 
(34) or daunorubicin (35) were more efficient in inhibiting 
tumor growth than the commercial preparations of these 
drugs. In multiple myeloma patients, the use of carmustine 
associated with the nanoemulsion resulted in amelioration 
of both clinical and laboratorial disease parameters (36). In 
addition, we showed that the use of nanoemulsions mark-
edly reduced drug toxicity in animal experiments (22,32-35) 
and in clinical trials (16-18,23,28,30,31,36).
Immunohistochemistry has been widely used to assess 
the presence of receptors in neoplastic breast tissues. Since 
the neoplastic disease processes do not produce defec-
tive lipoprotein receptors, it is expected that the receptor 
amounts detected by immunohistochemistry, with a high 
degree of specificity, are not dysfunctional. Determination 
of the uptake of the radioactively labeled nanoemulsion by 
tumor tissue, as performed in our previous studies (17), is 
the ultimate measurement of receptor function but does 
not discriminate among the different receptors involved 
in the uptake, such as the LDL receptor, LRP receptor or 
scavenger receptor class b member 1 (SRB1).
The novel findings described here regarding the status 
of lipoprotein receptors after chemotherapy could help to 
establish basic cellular mechanisms that may contribute to 
the design of future clinical assays dealing with nanotech-
nology treatment approaches. 
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